# Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment

> **NCT05957510** · PHASE2 · RECRUITING · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 66 (estimated)

## Conditions studied

- Small-cell Lung Cancer

## Interventions

- **DRUG:** Serplulimab
- **DRUG:** SOC

## Key facts

- **NCT ID:** NCT05957510
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-07
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05957510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05957510, "Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05957510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*